Back

Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Pharmacology and pharmacotherapy Diuretics HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Elfatih A Hasabo

Galway (Ireland)

5 More presentations in this session

Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report
Doctor M. Feola (Mondovi, IT)
Abstract Slides
Presentation thumbnail
Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?
Mr O. Chebbo (Montpellier, FR)
Abstract Slides Video
Presentation thumbnail
Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines
Doctor E. Higgisson (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials
Mr G. Yeap (GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Effect of sodium-glucose cotransporter-2 inhibitor (SGLT2-i) in patients with LVAD: a systematic review and meta-analysis
thumbnail
Congress Presentation
The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review
thumbnail
Congress Presentation
Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources